Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 41.17%. In terms of the factors that were most noteworthy in this DCF analysis for HZNP, they are:
The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.44 years is 0.45%; that's better than 74.17% of cash flow producing equities in the Healthcare sector, where it is classified.
The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 18.78% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 115 -- greater than 97.77% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
EDAP, MD, CMD, OSMT, and CRL can be thought of as valuation peers to HZNP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) was named as a 2020 Angels in Adoption® Honoree for the company’s outstanding advocacy for adoption of children living with rare diseases. The Congressional Coalition on Adoption Institute (CCAI), which coordinates the Angels in Adoption® Program, honored Horizon at its virtual gala on Sept. 30, 2020. The company was nominated by U.S. Senator Tammy Duckworth (D-IL). Horizon was recognized for its innovative #RAREis Adoption Fund p
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460]. Horizon’s MIRROR clinical program includes the completed multi-center, open-label trial as well as an ongoing randomized controlled trial (RCT). The tri
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of PEOPLE’s “50 Companies That Care” for 2020. The 2020 “50 Companies That Care” list spotlights 50 U.S. companies with 1,000 or more employees and their response to taking care of their employees, their communities and the world during the COVID-19 crisis. The list will be featured in the Sept. 14, 2020 print issue of PEOPLE. “It is a special honor to be recognized by PEOPLE and Great Pl
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,770,000 additional ordinary shares. The net proceeds to the Company from this offering are expected to be approximately $919.3 million, after deducting underwriting discounts and other estimated o